611 related articles for article (PubMed ID: 11573861)
1. Rhabdomyolysis and HMG-CoA reductase inhibitors.
Omar MA; Wilson JP; Cox TS
Ann Pharmacother; 2001 Sep; 35(9):1096-107. PubMed ID: 11573861
[TBL] [Abstract][Full Text] [Related]
2. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
3. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
Evans M; Rees A
Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Jamal SM; Eisenberg MJ; Christopoulos S
Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
6. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
7. Statin safety and drug interactions: clinical implications.
Bottorff MB
Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
[TBL] [Abstract][Full Text] [Related]
8. Statins and myotoxicity: a therapeutic limitation.
Tiwari A; Bansal V; Chugh A; Mookhtiar K
Expert Opin Drug Saf; 2006 Sep; 5(5):651-66. PubMed ID: 16907655
[TBL] [Abstract][Full Text] [Related]
9. Rhabdomyolysis and statin therapy: relevance to the elderly.
Sica DA; Gehr TW
Am J Geriatr Cardiol; 2002; 11(1):48-55. PubMed ID: 11773716
[TBL] [Abstract][Full Text] [Related]
10. Statin-induced rhabdomyolysis.
Schreiber DH; Anderson TR
J Emerg Med; 2006 Aug; 31(2):177-80. PubMed ID: 17044581
[TBL] [Abstract][Full Text] [Related]
11. Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin.
Schindler C; Thorns M; Matschke K; Tugtekin SM; Kirch W
Clin Ther; 2007 Jan; 29(1):172-6. PubMed ID: 17379057
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin-fluconazole causing rhabdomyolysis.
Shaukat A; Benekli M; Vladutiu GD; Slack JL; Wetzler M; Baer MR
Ann Pharmacother; 2003; 37(7-8):1032-5. PubMed ID: 12841814
[TBL] [Abstract][Full Text] [Related]
14. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.
Andreou ER; Ledger S
Can J Clin Pharmacol; 2003; 10(4):172-4. PubMed ID: 14712320
[TBL] [Abstract][Full Text] [Related]
15. [Rhabdomyolysis and acute renal failure secondary to statins].
Borrego FJ; Liébana A; Borrego J; Pérez del Barrio P; Gil JM; García Cortés MJ; Sánchez Perales C; Serrano P; Pérez Bañasco V
Nefrologia; 2001; 21(3):309-13. PubMed ID: 11471312
[TBL] [Abstract][Full Text] [Related]
16. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient.
Sica DA; Gehr TW
Curr Opin Nephrol Hypertens; 2002 Mar; 11(2):123-33. PubMed ID: 11856903
[TBL] [Abstract][Full Text] [Related]
17. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.
Catapano AL
Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768
[TBL] [Abstract][Full Text] [Related]
18. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.
Kind AH; Zakowski LJ; McBride PE
WMJ; 2002; 101(7):53-6. PubMed ID: 12426921
[TBL] [Abstract][Full Text] [Related]
19. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.
Maltz HC; Balog DL; Cheigh JS
Ann Pharmacother; 1999 Nov; 33(11):1176-9. PubMed ID: 10573315
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan
.
Hashiguchi M; Hakamata J; Shimizu M; Maruyama J; Shiga T; Mochizuki M
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):310-320. PubMed ID: 29701171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
